Prevent cancer preclinical drug development program: preclinical efficacy and endpoint biomarkers. Task order title: urinary bladder cancer prevention with two clinically-ready agents (everolimus…
Ended Awarded Last action
- Contract number
- 75N91020F00003
- Awardee
-
University Of Oklahoma UEI GY8NMUZQXVS7 Part of University Of Oklahoma
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $780,910
Award facts
- Opportunity
- Contract value 100% obligated
- $780,910.07 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Oklahoma City, OK 73104, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$4,250 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $785,160 |
About this award
The National Cancer Institute issued a delivery order to the University of Oklahoma (operating as the Board of Regents of the University of Oklahoma Health Sciences Center) on September 21, 2020, under the PREVENT Preclinical Drug Development Program IDIQ, with a ceiling value of $780,910.07 for preclinical efficacy studies on urinary bladder cancer prevention using everolimus and naproxen in combination.
The PREVENT Preclinical Drug Development Program is a National Cancer Institute IDIQ supporting cancer prevention drug development through multiple delivery orders. Place of performance is Oklahoma City, Oklahoma. The order is firm fixed price with ultimate completion on June 20, 2025.
Service Contract Inventory reporting shows declining labor engagement across the order's life. FY2021 invoiced $260 thousand at a derived rate of $91.94/hr with 1.4 FTEs and 2,825 contractor hours. FY2022 invoiced $346 thousand at $116.49/hr with 1.4 FTEs and 2,973 contractor hours. FY2023 peaked at $725 thousand invoiced at $343.96/hr with 1.0 FTEs and 2,107 contractor hours. FY2024 and FY2025 show substantial drawdown: $40 thousand in FY2024 at $29.52/hr with 0.7 FTEs and 1,369 contractor hours, followed by $17 thousand in FY2025 with 0.5 FTEs. The awardee self-performed all reported labor with no subcontractor engagement.
Description
Prevent cancer preclinical drug development program: preclinical efficacy and endpoint biomarkers. Task order title: urinary bladder cancer prevention with two clinically-ready agents (everolimus and naproxen)when administered in combination.
Quick answers
Who was awarded contract 75N91020F00003?
75N91020F00003 was awarded to University Of Oklahoma by National Cancer Institute (National Institutes of Health) on September 21, 2020.
How much is contract 75N91020F00003 worth?
The government has obligated $780,910 on 75N91020F00003.
Is contract 75N91020F00003 an order under another contract?
Yes. 75N91020F00003 is a delivery order under 75N91019D00020, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91020F00003 competed?
The extent of competition for 75N91020F00003 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award